Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nawrotowy glejak (rak mózgu, który powrócił po leczeniu)
- •Wiek co najmniej 18 lat
- •Dobre samopoczucie i sprawność fizyczna (ocena Karnofsky'ego co najmniej 70 procent)
- •Przynajmniej 3 miesiące przewidywanego przeżycia
- •Wcześniej otrzymało co najwyżej 3 rodzaje terapii
- •Choroba pogorszyła się po standardowym leczeniu pierwszego rzędu (napromienianie, chemioterapia)
- •Zdolność do przeprowadzenia badania rezonansem magnetycznym (MRI)
- •Prawidłowe wartości morfologii krwi i funkcji narządów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Northwestern University
Chicago, United States
Trial contact
Study Coordinator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.